These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 15888603

  • 1. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
    Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K, Danish Multiple Sclerosis Study Group.
    Neurology; 2005 Jul 12; 65(1):33-9. PubMed ID: 15888603
    [Abstract] [Full Text] [Related]

  • 2. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?
    Sorensen PS, Koch-Henriksen N, Flachs EM, Bendtzen K.
    Mult Scler; 2008 Jul 12; 14(6):837-42. PubMed ID: 18505772
    [Abstract] [Full Text] [Related]

  • 3. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S, European Interferon Beta-1a IM Dose-Comparison Study Investigators.
    Neurology; 2005 Jul 12; 65(1):40-7. PubMed ID: 16009883
    [Abstract] [Full Text] [Related]

  • 4. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM.
    Mult Scler; 2009 May 12; 15(5):601-5. PubMed ID: 19299439
    [Abstract] [Full Text] [Related]

  • 5. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
    Massart C, Gibassier J, de Seze J, Debouverie M, Moreau T, Pelletier J, Vermersch P, Edan G.
    Clin Chim Acta; 2008 May 12; 391(1-2):98-101. PubMed ID: 18249193
    [Abstract] [Full Text] [Related]

  • 6. Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?
    Sorensen PS, Koch-Henriksen N, Bendtzen K.
    Mult Scler; 2007 Jun 12; 13(5):616-21. PubMed ID: 17548440
    [Abstract] [Full Text] [Related]

  • 7. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS.
    Francis GS, Rice GP, Alsop JC, PRISMS Study Group.
    Neurology; 2005 Jul 12; 65(1):48-55. PubMed ID: 16009884
    [Abstract] [Full Text] [Related]

  • 8. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta.
    Farrell R, Kapoor R, Leary S, Rudge P, Thompson A, Miller D, Giovannoni G.
    Mult Scler; 2008 Mar 12; 14(2):212-8. PubMed ID: 17986510
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G, Barbarash O, Casset-Semanaz F, Jaber A, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B, RNF Study Group.
    Clin Ther; 2007 Jun 12; 29(6):1128-45. PubMed ID: 17692727
    [Abstract] [Full Text] [Related]

  • 10. Predictive markers for response to interferon therapy in patients with multiple sclerosis.
    Malucchi S, Gilli F, Caldano M, Marnetto F, Valentino P, Granieri L, Sala A, Capobianco M, Bertolotto A.
    Neurology; 2008 Mar 25; 70(13 Pt 2):1119-27. PubMed ID: 18272865
    [Abstract] [Full Text] [Related]

  • 11. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
    Boz C, Oger J, Gibbs E, Grossberg SE, Neurologists of the UBC MS Clinic.
    Mult Scler; 2007 Nov 25; 13(9):1127-37. PubMed ID: 17967840
    [Abstract] [Full Text] [Related]

  • 12. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity.
    Sominanda A, Rot U, Suoniemi M, Deisenhammer F, Hillert J, Fogdell-Hahn A.
    Mult Scler; 2007 Mar 25; 13(2):208-14. PubMed ID: 17439886
    [Abstract] [Full Text] [Related]

  • 13. Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patients.
    Lampasona V, Rio J, Franciotta D, Furlan R, Avolio C, Fazio R, Lavolpe V, Vincent A, Comi G, Trojano M, Montalban X, Martino G.
    Eur Cytokine Netw; 2003 Mar 25; 14(3):154-7. PubMed ID: 14656689
    [Abstract] [Full Text] [Related]

  • 14. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
    Hesse D, Sellebjerg F, Sorensen PS.
    Neurology; 2009 Aug 04; 73(5):372-7. PubMed ID: 19652141
    [Abstract] [Full Text] [Related]

  • 15. Neutralizing antibodies to interferon.
    Noronha A.
    Neurology; 2007 Jun 12; 68(24 Suppl 4):S16-22. PubMed ID: 17562846
    [Abstract] [Full Text] [Related]

  • 16. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
    Perini P, Calabrese M, Biasi G, Gallo P.
    J Neurol; 2004 Mar 12; 251(3):305-9. PubMed ID: 15015010
    [Abstract] [Full Text] [Related]

  • 17. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.
    Vartanian T, Sölberg Sørensen P, Rice G.
    J Neurol; 2004 Jun 12; 251 Suppl 2():II25-30. PubMed ID: 15264109
    [Abstract] [Full Text] [Related]

  • 18. Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells.
    Abdul-Ahad AK, Galazka AR, Revel M, Biffoni M, Borden EC.
    Cytokines Cell Mol Ther; 1997 Mar 12; 3(1):27-32. PubMed ID: 9287241
    [Abstract] [Full Text] [Related]

  • 19. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.
    Farrell RA, Espasandin M, Lakdawala N, Creeke PI, Worthington V, Giovannoni G.
    Mult Scler; 2011 Nov 12; 17(11):1333-40. PubMed ID: 21685230
    [Abstract] [Full Text] [Related]

  • 20. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE, Oger J, Grossberg LD, Gehchan A, Klein JP.
    J Interferon Cytokine Res; 2011 Mar 12; 31(3):337-44. PubMed ID: 21226608
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.